⌘+K

Equity Story

Near term

6-12 MONTHS

Key near-term drivers of the equity story include clinical progress, potentially de-risking study readouts and potential partnering transactions that could provide external validation and generate income. We view the VBX-1000 readout in Q1 2027 as the most important near-term catalyst. Positive data could further reduce development risk and materially strengthen the case for a third-party partnering agreement in 2027. Beyond this year, we see the FLEX-HCC readout, expected in H2 2027, as the catalyst with the greatest potential impact on the shares.

Long term

6+ YEARS

The longer-term story centres on Medivir advancing its pipeline towards regulatory approval and commercialisation. With three mid-stage assets targeting four indications, the company has reduced its reliance on a single programme and its exposure to asset-specific risk. A stronger shareholder base and improved financial position provide additional support for further development. We expect potentially registrational data readouts across key programmes within the next four to five years. Positive results could support regulatory submissions and, subject to approval, partnering and successful commercial execution, establish a path towards sustained profitability.

Key risks

  • Development risks remain significant, with its clinical assets in mid-stage development

  • Valuation rests on three assets and any clinical setbacks would have material effects on our valuation

  • Despite its strengthened financials, it is likely Medivir will need to raise additional capital to support further development of its programmes

  • A licensing agreement for fostrox or MIV-711 would represent a considerable upside to our valuation

Fair value range

Price

Fair range high value

Fair range low value

The upper end of our fair value range is derived from our SOTP analysis using a WACC of 12%, while the lower end is based on a 15% discount rate, reflecting continued risk aversion towards the biotechnology sector. The upper end assumes a gradual normalisation of investor sentiment and a more supportive valuation environment.

Valuation and methodology

Our valuation of Medivir is based on a SOTP model, where we assess each project over its patent lifespan. We include only projects with a clear path forward, whether driven by the company or a partner. For now, we have included fostrox, MIV-711 and MIV-701. Our forecasts are risk-adjusted according to the respective development phases.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB